Isotype selection for antibody‐based cancer therapy | Zendy

Vukovic N. | Zendy; Elsas A. | Zendy; Verbeek J. S. | Zendy; Zaiss D. M. W. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Isotype selection for antibody‐based cancer therapy

Author(s) -

Vukovic N.,

Elsas A.,

Verbeek J. S.,

Zaiss D. M. W.

Publication year - 2021

Publication title -

clinical & experimental immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.329

H-Index - 135

eISSN - 1365-2249

pISSN - 0009-9104

DOI - 10.1111/cei.13545

Subject(s) - isotype , monoclonal antibody , antibody , immunology , effector , immune system , cancer , biology , antibody dependent cell mediated cytotoxicity , cancer research , medicine , genetics

Different mechanisms play a role in the anti‐tumour effect of mAbs and both target engagement with the Fab arm as well as Fc‐mediated effector functions contribute to the efficacy of treatment. As Ig isotypes differ in their ability to bind to FcRs on immune cells as well as in their ability to activate complement, they differ in the immune responses they activate. Therefore, the choice of antibody isotype for therapeutic mAbs is dictated by its intended mechanism of action. Here, we discuss the current knowledge of the therapeutic effector functions of different isotypes and Fc‐engineering strategies to improve mAbs application.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research